Please login to the form below

Not currently logged in
Email:
Password:

Descovy

This page shows the latest Descovy news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

Its main rival is expected to be Gilead’s new fixed-dose regimen Biktarvy, which combines integrase inhibitor bictegravir with the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide)

Latest news

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    that adds integrase inhibitor bictegravir to the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide) product. ... Descovy was approved in the US last year and is often prescribed alongside Tivicay.

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    Gilead plans fightback against HIV arch-rival ViiV. Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq. ... Gilead has reported the results of four phase III trials of a new HIV combination therapy pairing its Descovy

  • Gilead's Truvada cleared for HIV prevention in EU Gilead's Truvada cleared for HIV prevention in EU

    The new emtricitabine/TAF-based product - called Descovy - was approved in the US and EU earlier this year. ... Gilead has said it is data from animals suggesting that Descovy has equivalent activity to Truvada as PrEP, but has not yet decided what

  • HIV prevention pill heads July CHMP recommendations HIV prevention pill heads July CHMP recommendations

    Gilead is in the process of rolling out a new version of the drug - called Descovy - based on an improved tenofovir salt and was approved in the EU in April.

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    The once-daily, single-tablet combines TAF with emtricitabine - a dual therapy sold as Descovy - with Johnson &Johnson's Edurant (rilpivirine). ... Gilead is in the process of replacing all of its TDF-based HIV products with TAF and in addition to

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics